James Wells

Associate Professor James Wells directs immunology research at the University of Queensland's Frazer Institute and Dermatology Research Centre. His laboratory develops CD8+ T-cell therapies for skin cancer, with patented drug Q2361 targeting immunosuppression in transplant recipients. Wells' NIH-funded work delineates intrinsic pathways regulating T-cell function in cutaneous malignancies.

Research integrates molecular biology with clinical translation, including microarray patches for vaccine delivery and combination checkpoint blockade strategies. Current projects investigate double-positive T-cell biology and myeloid cell-mediated immunosuppression.